EEG: Old Method to Lend New Help in AD Drug Development?
CTAD attendees got an earful about an arguably neglected topic in Alzheimer’s research, that is, the use of event-related potentials (ERP) as biomarkers of disease...
588 RESULTS
Sort By:
CTAD attendees got an earful about an arguably neglected topic in Alzheimer’s research, that is, the use of event-related potentials (ERP) as biomarkers of disease...
Findings strengthen the case for using biomarkers to determine who is at risk for AD before symptoms develop...
Clifford Jack's hypothetical model showing biomarkers emerging at different stages of AD surged to the top of the Most-Popular-Slide-at-Conferences chart...
Researchers got something new to think about with respect to how the cell controls expression of the disease-linked gene progranulin...
Results of a nine-year longitudinal study indicate that women with the highest amounts of certain types of ceramide in their blood are more likely to develop Alzheimer’s disease...
Among global initiatives aimed at understanding how biomarkers elucidate the progression of Alzheimer’s disease, DESCRIPA appears to do much with little...
Merck’s BACE inhibitor development program began enrolling last month for an 18-month Phase 2/3 trial of its lead compound (MK-8931) in mild to moderate AD...
Scientists quipped about Florence as a fitting setting for what they perceive to be a resurgence of the amyloid hypothesis after a beleaguered period of setbacks...
The 11th AD/PD Conference hosted a day-long exchange of new imaging data and discussion of current challenges for the research community in these two disorders...
The Alzheimer’s Disease Neuroimaging Initiative steering committee gathered to exchange the latest developments in ADNI 2...
New research boosts support for the use of magnetic resonance imaging (MRI) to identify seniors at the cusp of cognitive decline...
An excess of sirtuin one-ups mutant huntingtin in mice, saving neurons and delaying Huntington’s disease...
Researchers studying amyotrophic lateral sclerosis (ALS) have plenty of drug ideas to try, but a great problem in figuring out if they work or not...
Anticipating future clinical trials for Huntington’s disease, researchers are seeking sensitive measures that will predict onset and track progression...
In the quest for a Huntington’s disease biomarker—one that reliably tracks disease progress and therapeutic response—researchers have so far come up short...